
© 2025 Moneycab
Realtime | Geld | Brief | Zeit |
---|---|---|---|
63,08 | 63,64 | 29.03. | |
63,01 | 63,49 | 28.03. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Sa | Novo Nordisk: Neue Diabetes-Pille reduziert kardiovaskuläre Risiken | ||
Sa | Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years | ||
Sa | Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 | Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data... ► Artikel lesen | |
Sa | Novo says Ozempic succeeded in late-stage trial for peripheral artery disease | ||
Sa | Novo Nordisk A/S: Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025 | Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD) in the phase 3 STRIDE trial1.Data were presented at the American College... ► Artikel lesen |